SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth.
Sign Up to like & getrecommendations! Published in 2020 at "American journal of obstetrics and gynecology"
DOI: 10.1016/j.ajog.2020.04.001
Abstract: B16 JULY 20 In late 2019, results from the Progestin’s Role in Optimizing Neonatal Gestation (PROLONG) trial were published showing no benefit of weekly injections of 17-alpha hydroxyprogesterone caproate (17-)HPC) from 16-20 weeks of gestation… read more here.
Keywords: smfm statement; alpha hydroxyprogesterone; hydroxyprogesterone caproate; statement use ... See more keywords
Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention
Sign Up to like & getrecommendations! Published in 2021 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2021.1933928
Abstract: Abstract Objective To describe the use of and adherence to 17-alpha hydroxyprogesterone caproate (17-OHPC), explore factors associated with its utilization and adherence, and to investigate the outcomes of 17-OHPC in a real-world setting. Methods The… read more here.
Keywords: alpha hydroxyprogesterone; utilization adherence; preterm birth; hydroxyprogesterone caproate ... See more keywords